182570-26-9

Usage

Uses

Used in Scientific Research:
6-Methoxy-Chroman-3-Carboxylic Acid is used as a research compound for its unique structural properties, which can be explored for various scientific applications. Its ether and carboxylic acid characteristics may offer insights into new chemical reactions or interactions within the research context.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 6-Methoxy-Chroman-3-Carboxylic Acid is used as a potential lead compound for drug discovery. Its structural features may be harnessed to develop new therapeutic agents, particularly in the areas of medicinal chemistry where its properties could be exploited to create novel drugs with specific therapeutic targets.
Used in Chemical Synthesis:
6-Methoxy-Chroman-3-Carboxylic Acid is used as a synthetic intermediate in the preparation of more complex molecules. Its chroman ring system and functional groups make it a valuable building block for the synthesis of a wide range of chemical products, including potential pharmaceuticals and specialty chemicals.
Used in Material Science:
6-Methoxy-Chroman-3-Carboxylic Acid may be utilized in material science applications, where its unique chemical structure could contribute to the development of new materials with specific properties, such as improved stability, reactivity, or selectivity in various chemical processes.

Upstream product

• 885271-71-6 C₁₃H₁₆O₄ 
• 672-13-9 2-hydroxy-5-methoxybenzaldehyde 
• 2495-35-4 benzylacrylate 
• 57543-71-2 6-methoxy-2H-chromene-3-carbonitrile 
• 57543-62-1 3-caboxy-6-methoxy-2H-1-benzopyran 

Downstream Products

• 1213262-03-3 C₁₇H₁₆BrNO₄ 
• 1161763-22-9 C₁₈H₁₈BrNO₄ 
• 1161762-49-7 C₁₇H₁₆BrNO₃ 
• 182570-28-1 (S)-6-methoxychroman-3-carboxylic acid 
• 1094472-13-5 SR 3850 

Relevant academic research and scientific papers

Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide as potent and isoform selective ROCK2 inhibitors

ROCK1 and ROCK2 are highly homologous isoforms. Accumulated studies indicate that they have distinct different functions, and the development of isoform selective ROCK inhibitors will pave new roads for the treatment of various diseases. In this work, a series of amide-chroman derivatives were synthesized and biologically evaluated in order to develop potent and isoform selective ROCK2 inhibitors. Remarkably, (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide ((S)-7c) possessed ROCK2 inhibitory activity with an IC50 value of 3 nM and 22.7-fold isoform selectivity (vs. ROCK1). Molecular docking indicated that hydrophobic interactions were the key element for the high potency and isoform selectivity of (S)-7c. The binding free energies predicted by MM/GBSA were in good agreement with the experimental bioactivities, and the analysis of individual energy terms suggested that residue Lys105 in ROCK1 or Lys121 in ROCK2 was the key residue for the isoform selectivity of (S)-7c.

The development of benzimidazoles as selective rho kinase inhibitors

Rho Kinase (ROCK) is a serine/threonine kinase whose inhibition could prove beneficial in numerous therapeutic areas. We have developed a promising class of ATP-competitive inhibitors based upon a benzimidazole scaffold, which show excellent potency toward ROCK (IC50 10 nM). This report details the optimization of selectivity for ROCK over other related kinases such as Protein kinase A (PKA).

Chroman-3-amides as potent Rho kinase inhibitors

Inhibition of Rho kinase (ROCK) is an attractive strategy for the treatment of diseases such as hypertension, glaucoma, and cancer. Here we report chroman-3-amides as highly potent ROCK inhibitors with sufficient kinase selectivity, excellent cell activit